City of Hope’s Post

Treat Kidney Cancer With Non-Invasive CyberKnife: CyberKnife radiosurgery is a highly effective tool in the treatment of primary and metastatic kidney cancer, also known as Renal Cell carcinoma. Thanks to breakthrough advances in technology, the CyberKnife uses radiation to ablate kidney tumors and stop them from growing. The extremely high doses of radiation target only the tumor while sparing healthy normal tissues. Who Is a Candidate for CyberKnife?  Many people who have been told that they are not a candidate for surgery maybe be a candidate for CyberKnife Stereotactic Radiotherapy treatment. We can also treat post-operative patients and metastatic disease. What To Expect from CyberKnife Kidney Cancer Treatment?  Most patients can be treated in 1-5 treatments over a period of a few days. The treatment itself is comfortable, and patients can expect little to no side effects after undergoing CyberKnife.  What Types of Kidney Tumors Can CyberKnife Treat?  Clear Cell Carcinoma (70% of kidney cancers), Papillary Renal Cell Carcinoma (10% of kidney cancers), Chromophobe Renal Cell Carcinoma (5% of kidney cancers), and several severe rare types including Duct Renal Cell (very aggressive), Multilocular Cystic Renal Cell (good prognosis), Medullary Carcinoma, renal Mucinous Tubular and Spindle Cell Carcinoma (less than 1% of kidney cancers). There are also unclassified Renal Cell Carcinomas that do not fit any category because they have more than one type and are 3-5% of all kidney cancers and are very aggressive, these require prompt treatment. If you have kidney cancer, it’s critical to understand your treatment options. To find out if you are a candidate for life-saving CyberKnife radiosurgery, call CyberKnife Center of Miami at (800) 204-0455. CyberKnife Center of Miami "The Beam of Life" #CyberknifeTreatment #kidneycancertreatment

A groundbreaking study has emerged as a beacon of hope for individuals battling lung cancer. Recent research has revealed that administering immunotherapy both before and after surgery can significantly enhance survival rates for lung cancer patients. The study, published in NEJM Group, highlights the use of nivolumab, a form of immunotherapy, in conjunction with chemotherapy, marking a pivotal shift in treatment protocols. Patients who received this combined treatment were more likely to remain cancer-free 18 months post-surgery, showcasing a remarkable improvement in event-free survival. This is particularly noteworthy for non-small cell lung cancer, which accounts for a substantial portion of lung cancer diagnoses and is often linked to smoking. The CheckMate 77T trial, an international phase three study, has been instrumental in demonstrating the efficacy of nivolumab. By integrating it both pre- and post-surgery, the trial has set a new standard in the fight against lung cancer, offering patients a greater chance at a cancer-free future. As we navigate the complexities of cancer treatment, this study serves as a testament to the power of innovation and the importance of ongoing research. It’s a step forward that could potentially transform the landscape of lung cancer care, providing a new ray of hope for patients and their families. #LungCancerAwareness #Immunotherapy #CancerResearch #HealthcareInnovation https://lnkd.in/gTjDZGrT

Patients with cancer suffer from receiving chemotherapy. 😔 The notorious group of drugs are a major challenge in the treatment journey for breast cancer patients. But can some patients avoid it❓️❓️ Recently, the PHERGain study was published with impressive results in terms of avoiding chemotherapy in the neoadjuvant treatment of HER2 positive breast cancer. In this study, 285 patients with stage I-III HER2+ breast cancer received dual anti-HER2 blockade (trastuzumab +pertuzumab) with or without hormonal treatment. PET-CT was used to assess the response to treatment after 2 cycles. If responsive by PET, patients continued for 6 cycles then surgery. Finally, chemotherapy was offered for non-PCR or non-responders. A total of 227 (80%) out of 285 patients were PET responders, of whom 86 (37·9%), achieved PCR without chemotherapy. In the 3 year iDFS results, ~95% were disease free which is much better than historical control. Such results provides a new hope for breast cancer patients where chemotherapy is considered inevitable. #ResearchersToolbox #breastCancer #cancerresearch #cancer #publication

Treat Kidney Cancer With Non-Invasive CyberKnife: CyberKnife radiosurgery is a highly effective tool in the treatment of primary and metastatic kidney cancer, also known as Renal Cell carcinoma. Thanks to breakthrough advances in technology, the CyberKnife uses radiation to ablate kidney tumors and stop them from growing. The extremely high doses of radiation target only the tumor while sparing healthy normal tissues. Who Is a Candidate for CyberKnife?  Many people who have been told that they are not a candidate for surgery maybe be a candidate for CyberKnife Stereotactic Radiotherapy treatment. We can also treat post-operative patients and metastatic disease. What To Expect from CyberKnife Kidney Cancer Treatment?  Most patients can be treated in 1-5 treatments over a period of a few days. The treatment itself is comfortable, and patients can expect little to no side effects after undergoing CyberKnife.  What Types of Kidney Tumors Can CyberKnife Treat?  Clear Cell Carcinoma (70% of kidney cancers), Papillary Renal Cell Carcinoma (10% of kidney cancers), Chromophobe Renal Cell Carcinoma (5% of kidney cancers), and several severe rare types including Duct Renal Cell (very aggressive), Multilocular Cystic Renal Cell (good prognosis), Medullary Carcinoma, renal Mucinous Tubular and Spindle Cell Carcinoma (less than 1% of kidney cancers). There are also unclassified Renal Cell Carcinomas that do not fit any category because they have more than one type and are 3-5% of all kidney cancers and are very aggressive, these require prompt treatment. If you have kidney cancer, it’s critical to understand your treatment options. To find out if you are a candidate for life-saving CyberKnife radiosurgery, call CyberKnife Center of Miami at (800) 204-0455. CyberKnife Center of Miami "The Beam of Life" #CyberknifeTreatment #kidneycancertreatment

NSCLC is any type of epithelial lung cancer other than small cell lung cancer (SCLC). The most common types of NSCLC are squamous cell carcinoma, large cell carcinoma, and adenocarcinoma, but there are several other types that occur less frequently, and all types can occur in unusual histological variants. Prognostic Factors: Increasing stage. Presence of pulmonary or constitutional symptoms. Large tumor size (>3 cm). Metastases to multiple lymph nodes within a TNM-defined nodal station. Vascular invasion. Molecular features: EGFR and ALK mutations predominate in adenocarcinomas that develop in nonsmokers, and KRAS and BRAF mutations are more common in smokers or former smokers. Beside surgery therapy, the adjuvant therapy can divided in chemotherapy, radiation therapy (external or brachytherapy) and immunotherapy. Estimated new cases and deaths from lung cancer (NSCLC and SCLC combined) in the United States in 2024 New cases: 234,580. Deaths: 125,070. Lung cancer is the leading cause of cancer-related mortality in the United States. The 5-year relative survival rate from 2013 to 2019 for patients with lung cancer was 25%. The 5-year relative survival rate varies markedly for patients diagnosed at local stage (63%), regional stage (35%), or distant stage (8%). NSCLC CancerGov: https://lnkd.in/gMAVn86E

SBRT and Oligoprogression in NSCLC and Breast Cancer: Is there a role for SBRT in this scenario? Oligoprogression, an oncological term coined by Hellman and Weichselbaum in 1995, has gained increasing relevance in therapeutic decision-making. This concept urges us to personalize and delve into the tumor biology of patients experiencing it. This Phase II study is a randomized controlled clinical trial assessing the efficacy of stereotactic body radiotherapy (SBRT) in patients with metastatic breast cancer or non-small-cell lung adenocarcinoma (NSCLC) exhibiting oligoprogression. Oligoprogression is defined as the presence of five or fewer progressive lesions identified by PET-CT or CT after receiving at least one first-line systemic therapy. Results: - The median follow-up was 11.6 months for the standard-of-care group and 12.1 months for the SBRT group. - Progression-free survival (PFS) was 3.2 months for the standard-of-care group versus 7.2 months for the SBRT group. - Median progression-free survival was higher for NSCLC patients in the SBRT group compared to the standard-of-care group (10.0 months vs. 2.2 months). - No significant difference was observed for patients with breast cancer (4.4 months vs. 4.2 months). Conclusions: Progression-free survival was increased in the SBRT plus standard-of-care group compared with standard of care only. Oligoprogression in patients with metastatic NSCLC could be effectively treated with SBRT plus standard of care, leading to more than a four-times increase in progression-free survival compared with standard of care only. By contrast, no benefit was observed in patients with oligoprogressive breast cancer. #radiationoncology #radiotherapy #radonc #SBRT #oncology #NSCLC #lungcancer #breast #breastcancer #neumonology https://lnkd.in/dWg288cC

Many patients diagnosed with with stage II and III colon cancer go straight to chemotherapy treatment after surgery to reduce the likelihood that the cancer will come back. 🔬 However, promising results from the BESPOKE clinical trial suggest that there may be a blood test that physicians could use to determine who would benefit from chemotherapy and who could safely skip it. 🧬 Cancer cells have unique variants of proteins and DNA that can be shed into the bloodstream that are called circulating tumor DNA (ctDNA). 🩸 In the BESPOKE clinical trial, a blood test unique to a patient's specific cancer was designed to detect traces of ctDNA, which would show the presence of cancer. “This test brings us closer to finding the cancer. If you can detect cancer in a blood sample several months after surgery, you can get ahead of the game,” said Timothy Cannon, MD, Co-Director of the Gastrointestinal Cancer Program at Inova Schar Cancer and a participating physician in the BESPOKE clinical trial. Learn more: https://bit.ly/3vhiiph #CancerResearch #ColonCancer #CancerCare

📣 CANCER CURRENTS: Dr. Mark Ball, an attending surgeon in the Urologic Oncology Branch of the National Cancer Institute (NCI), spoke about early clinical trial results that show the potential efficacy of nivolumab injections for the treatment of advanced kidney cancer. Nivolumab is an immune checkpoint inhibitor, a type of immunotherapy that helps immune cells attack cancer. It is used to treat more than 10 types of cancer. ➡ Read more: https://go.nih.gov/ejhsQd9 Dr. Ball specializes in the surgical treatment of kidney and adrenal tumors and performs robotic, laparoscopic and open surgery. He has particular expertise in robotic partial nephrectomy and robotic partial adrenalectomy for hereditary kidney cancer syndromes, and has removed over 1,000 kidney tumors during partial nephrectomy procedures. #CancerResearch #KidneyCancer #Health #Immunotherapy #Medicine

Study gives more insight into advanced form of thyroid cancer treatment, ET HealthWorld Illinois: According to the findings of a multicenter phase II clinical trial led by the University of Chicago Medicine Comprehensive Cancer Centre, adding an immunomodulatory agent to treatment with the targeted tyrosine kinase inhibitor (TKI) cediranib did not improve outcomes in patients with differentiated thyroid cancer (DTC), which develops from thyroid follicular cells. The findings of the research were published in Annals of Oncology on May 13, 2023. The majority of DTC patients are successfully treated. However, a tiny percentage of people acquire cancer that recurs or spreads to other parts of the body, rendering standard treatments such as surgery, … Read More » Illinois: According to the findings of a multicenter phase II clinical trial led by the University of Chicago Medicine Comprehensive Cancer Centre, adding an immunomodulatory agent to treatment with the targeted tyrosine kinase inhibitor (TKI) cediranib did not improve outcomes in patients with differentiated thyroid cancer (DTC), which develops from thyroid follicular cells. The findings of the research were published in Annals of Oncology on May 13, 2023. The majority of DTC patients are successfully treated. H...